Trials / Unknown
UnknownNCT02485106
Rifaximin Use in Severe Alcoholic Hepatitis
Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- Saint Vincent's Hospital, Korea · Academic / Other
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | 400mg three times per day for 28 days |
| DRUG | Corticosteroid or pentoxifylline | Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-12-01
- First posted
- 2015-06-30
- Last updated
- 2015-06-30
Source: ClinicalTrials.gov record NCT02485106. Inclusion in this directory is not an endorsement.